Johnson & Johnson Gets FDA Approval for Lung Cancer Treatment

 Johnson & Johnson's Rybrevant Faspro was approved as a treatment for people with lung cancer by the Food and Drug Administration.

Rybrevant Faspro was approved across all indications for subcutaneous administration for patients with epidermal growth factor receptor-mutated non-small cell lung cancer, J&J said Wednesday.

The approval is based on the results of a Phase 3 trial, which met both co-primary pharmacokinetic endpoints.

Patients treated showed longer duration of response, improved progression-free survival and longer overall survival.

Rybrevant Faspro enables a simpler, shorter administration time for a first-line combination regime when combined with Lazcluze.

Rybrevant is approved in the U.S. across four indications in that specific type of lung cancer.

https://www.morningstar.com/news/dow-jones/202512179862/johnson-johnson-gets-fda-approval-for-lung-cancer-treatment